ability to obtain write inform consent from the patient or caregiver a a surrogate meet national institute on aging-alzheimer 's association workgroups criterion for probable ad dementia mckhann et al 2011 with symptom onset age 70 presence of epileptiform activity on initial screening m/eeg willing and able caregiver who have daily contact with the subject mini-mental state examination mmse score of 18 at the initial screening assessment and/or clinical dementia rating cdr 2 within 180 day of enrollment subject and caregiver must be able to comply with prescribe regime of study treatment throughout the course of the study and meet the require time commitment of four day of in-person visit any concurrent fda-approved treatment for ad such a donepezil galantamine or rivastigmine and memantine must be stable for at least 2 month prior to enrollment other medication except those list under exclusion criterion be allow a long a the dose be stable for 30 day prior to enrollment 